Biotech CEO on where we are in the fight to cure cancer

Jonathan Lim's Professional Trajectory:

• Originally trained as a general surgeon at New York Hospital after pre-med studies at Stanford and McGill.
• Spent two years at Dana-Farber Cancer Institute conducting cancer epidemiology research and earned an MPH in Healthcare Management from Harvard.
• Joined McKinsey & Company for two years before accepting a CEO role at Halozyme, then a four-person startup, in 2003.
• Became CEO of Halozyme at age 31, starting with only three months of cash and zero VC investment.
• Led Halozyme from an OTC bulletin board listing to an American Stock Exchange listing (1 year later) and a NASDAQ listing (2.5 years later).
• Halozyme signed a pivotal deal with Roche in 30 days at the end of 2006, becoming the fourth-best performing stock on the Wall Street Journal that year.
• Current Halozyme revenue guidance is approximately $1 billion within the next few years.

Entrepreneurial Venture History (City Hill Ventures):

• Founded City Hill Ventures, a family office fund focusing on life science and healthcare technology.
• Co-founded and led multiple biotech companies, including Eclipse Therapeutics (spinout from Biogen IDEC) and Ignita (acquired by Bionomics in 2018).
• Founded Bonti in 2015 (a spinout from Allergan technology), which was also acquired in 2018.
• Co-founded Boundless Bio with Paul Michel and ARCH to develop diagnostics and therapies targeting extra-chromosomal DNA (ecDNA).

Araska Therapeutics Strategic Overview:

• Mission statement "Arasca" is a portmanteau of "erase cancer" and "eradicate RAS-driven cancer."
• Company tagline emphasizes the goal of increasing long-term remission rates for cancer patients beyond the current ~20% seen with checkpoint inhibitors.
• Focuses on the RAS/MAP kinase pathway as a primary target area.
• Lead Clinical Program: Naporafenib (Nap-RAF), a pan-RAF inhibitor, is currently in the clinic for NRAS mutant melanoma (targeting ~50,000 patients in the US).
• Strategic Pivot (2019–2024):
  • Shifted from an early RAS discovery focus to an IRC targeting program after going public.
  • In-licensed Nap-RAF from Novartis but pivoted again to acquire two new RAS-targeting assets to address larger unmet needs.
  • Recently in-licensed a pan-RAS molecular glue (ERAS-15) described as having higher potency than competitors' candidates.
  • Secured a second RAS program: a KRAS selective pan-KRAS small molecule inhibitor.
• Therapeutic Strategy: Plans to combine these new RAS inhibitors with standard of care in pancreatic, lung, and colon cancers, and potentially with each other to treat acquired resistance mutations.
• The company prioritized capital preservation after its 2021 IPO, saving cash to navigate a potential downturn in the biotech market.

Biotech Industry Trends & Challenges:

• ecDNA Discovery: The field is recognizing extra-chromosomal DNA (ecDNA) as a major driver of oncogene amplification, metastasis, and recurrence, complicating traditional genetic sequencing approaches.
• New Modalities: Industry progress is driven by non-traditional modalities, such as molecular glues (e.g., RevMed's RMC6236) that target historically "undruggable" RAS wild-type and active GTP states.
• Market Environment: Described as "Darwinian," with intense competition for investor capital, partner attention, and talent forcing rapid pivots.
• Investor Expectations: The market has shifted from a platform-focused cycle back to a product-focused cycle, prioritizing clear proof of concept and patient impact data.
• Forward-Looking Prediction: Lim predicts the next 5 years will feature significant leaps in shutting down oncogene drivers through new chemical modalities and combinations, potentially increasing the "cure" rate in cancer.

City Hill Arts & Media Ventures:

• Lim launched City Hill Arts to produce stories focusing on unifying themes of love, kindness, and hope ("revitalizing people, planet, and perspective").
• Current Slate:
  • My Penguin Friend: A feature film based on a true story of a Brazilian fisherman and an Argentinian penguin; 80% of the film features real penguins, with 15% CGI and 5% animatronics.
  • The Secret Art of Human Flight: A grounded sci-fi film releasing simultaneously in theaters and on streaming (day-and-date release).
• Industry Parallels: Lim draws direct comparisons between biotech and film production, citing:
  • Similar development timelines (8–13 years from conception to release).
  • The existence of "development hell" in both sectors.
  • The necessity of a portfolio approach due to the low probability of success for individual projects.
  • The reliance on "hits" to offset the costs of failures.